glp-1 supply shortage news november 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots GLP-1 Weight Loss Drug Enforcement

doi: 10.1016/j.molcel.2015.06.011 46 ZhangXHouLGuoZWangGXuJZhengZet al

With GLP-1s already approved for treating type 2 diabetes and cardiovascular disease, researchers now are assessing the efficacy of these drugs for other medical conditions

Read review Dihexa for Sleep Apnea Brain Fog OSA & hypoxemia, REM CA1 hippocampal loss (UC Irvine May 2025), Zepbound (tirzepatide) FDA approval Dec 2024 (SURMOUNT-OSA), NICE NG202, and the ~13 million UK adults estimated to have OSA

In rare cases, hGH has been linked to diabetes, certain cancers and "pseudotumor cerebri syndrome," which builds pressure in the brain and triggers intense, frequent headaches and changes in vision